A5084710848- Prostate Cancer Treatment and Research
- Ethics in Clinical Research
- Prostate Cancer Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- BRCA gene mutations in cancer
- Inflammatory Biomarkers in Disease Prognosis
- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Genetic factors in colorectal cancer
- Viral-associated cancers and disorders
- Advanced Radiotherapy Techniques
- Lung Cancer Research Studies
- Renal cell carcinoma treatment
- Head and Neck Cancer Studies
- Statistical Methods in Clinical Trials
- Neuroblastoma Research and Treatments
- Cancer-related cognitive impairment studies
- Multiple and Secondary Primary Cancers
- Polyomavirus and related diseases
- Parkinson's Disease Mechanisms and Treatments
- Genetics and Neurodevelopmental Disorders
- Cancer Genomics and Diagnostics
- Hormonal and reproductive studies
- Cancer Immunotherapy and Biomarkers
Florida Urology Associates
2023
Tampa General Hospital
2023
University of Maryland, Baltimore
2014-2017
University of Maryland Medical Center
2014-2016
University of Pennsylvania
2016
University of Maryland Medical System
2015
Importance Hypofractionated radiation therapy (RT) for prostate cancer has been associated with greater acute grade 2 gastrointestinal (GI) toxic effects compared conventionally fractionated RT. Objective To evaluate whether a hyaluronic acid rectal spacer could (1) improve dosimetry and (2) affect or higher GI hypofractionated Design, Setting, Participants This randomized clinical trial was conducted from March 2020 to June 2021 among 12 centers within the US, Australia, Spain, 6-month...
Elevated neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte ratios (PLR) may represent markers of a suboptimal host immune response to cancer have been shown correlate with prognosis in multiple tumor types across different treatment modalities, including radiation therapy. Limited data suggest that NLR predict for survival disease control patients receiving selective internal therapy (SIRT). The correlation between clinical outcomes change PLR after SIRT has not evaluated.We...
Prostate cancer (PCa) patients with pathogenic/likely pathogenic germline variants (PGVs) in predisposition genes may be eligible for U.S. Food and Drug Administration-approved targeted therapies, clinical trials, or enhanced screening. Studies suggest that are missing genetics-informed care due to restrictive testing criteria.
Identification of pathogenic germline variants in patients with prostate cancer can help inform treatment selection, screening for secondary malignancies, and cascade testing. Limited real-world data are available on clinician recommendations following genetic testing cancer.
You have accessJournal of UrologyProstate Cancer: Markers I (MP41)1 May 2024MP41-08 UTILIZING PATIENT-REPORTED OUTCOMES TO ASSESS THE IMPACT OF UNIVERSAL GERMLINE GENETIC TESTING FOR PROSTATE CANCER Neal Shore, Christopher M. Pieczonka, Sean Heron, Mukaram Gazi, David J. Cahn, Laurence Belkoff, Aaron D. Berger, Brian Mazzarella, Morris, Joseph Veys, Richard Bevan-Thomas, Alexander Engelman, Paul Dato, Robert Cornell, R. Wise, Mary Kay Hardwick, Kathryn E. Hatchell, Brandie Heald, L....
10504 Background: Pathogenic/likely pathogenic (P/LP) germline genetic variants are estimated to occur in 10-15% of all prostate cancer (PCa) patients. However, testing for PCa patients is underutilized, partially due complicated and restrictive guidelines developed at a time when the cost was high. We conducted study based community urology clinics determine incidence P/LP who met did not meet NCCN 2019 criteria. Methods: An IRB-approved, multicenter, prospective registry initiated with 15...
You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History I (PD13)1 Sep 2021PD13-10 UNIVERSAL GERMLINE TESTING OF PROSTATE CANCER PATIENTS: ARE GENETIC GUIDELINES AN IMPEDIMENT TO PRECISION THERAPY? Neal Shore, David Cahn, Mukaram Gazi, Christopher Pieczonka, Laurence Belkoff, Sean Heron, Rishi Modh, Brian Mazzarella, Aaron Berger, Joseph Veys, Charles Idom, Morris, Gautam Jayram, Alexander Engelman, Richard Bevan-Thomas, Sarah Nielsen, Mary Kay Hardwick, Kathryn E....
You have accessJournal of UrologyCME1 Apr 2023PD21-11 REAL WORLD IMPACT OF GERMLINE GENETIC TESTING ON CLINICAL DECISION MAKING FOR PROSTATE CANCER PATIENTS Neal Shore, Christopher Pieczonka, Mukaram Gazi, Sean Heron, Rishi Modh, David Cahn, Laurence H Belkoff, Aaron Berger, Brian Mazzarella, Morris, Joseph Veys, Alexander Engelman, Paul Dato, Richard Bevan-Thomas, Robert Cornell, Wise, Charles Idom, Mary Kay Hardwick, Paige Layman, Kathryn Hatchell, Brandie Heald, Sarah Young, L Nussbaum,...
10607 Background: Germline genetic testing (GGT) affords prostate cancer (PCa) patients (pts) opportunities for targeted therapies, prevention and cascade testing. Patient-reported outcomes (PRO) can evaluate physician effectiveness in promoting patient test comprehension clinical decision making, which are critical to realize the benefits of GGT. PROs from a large PCa GGT study among urologists were analyzed. Methods: A prospective enrolled unselected pts 15 primarily community urology...
10500 Background: Approximately 10-15% of prostate cancer (PCa) patients (pts) have a pathogenic germline variant (PGV). Identification PGV has important implications affecting decisions regarding screening, treatment selection, and family cascade testing. There exists limited data documenting real world recommendations post genetic testing (GGT). This study was designed to collect clinician reported outcomes from PCa pts who underwent GGT. Methods: An IRB-approved, nationwide, prospective...